Omics Analysis Services for Bladder Cancer
Omics analysis refers to the comprehensive study of large-scale biological data generated from various high-throughput technologies, such as genomics, transcriptomics, proteomics, and metabolomics. Alfa Cytology provides comprehensive preclinical CRO services in the field of bladder cancer, offering a wide range of omics analysis services.
Omics Analysis in Bladder Cancer
Bladder cancer is the most common urinary tract malignancy, with a substantial global burden. Traditional diagnostic and therapeutic methods have limitations in terms of accuracy and sensitivity. Therefore, there is a need for innovative approaches that can provide more comprehensive and precise information about bladder cancer.
Omics analysis, encompassing genomics, transcriptomics, proteomics, metabolomics, and microbiomics, offers a holistic view of the molecular landscape of bladder cancer. By analyzing these different omics layers, researchers can uncover molecular signatures, identify potential biomarkers, understand disease mechanisms, and develop targeted therapies.
DNA
Genomics
RNA
Transcriptomics
Protein
Proteomics
Metabolite
Metabolomics
Cell
Single-Cell Omics
Tissue
Spatial omics
Fig.1 Our omics analysis includes genomics, transcriptomics, proteomics, metabolomics, single-cell omics, and spatial omics.
| Analysis |
Description |
Applications |
| Genomic Analysis |
Study of genetic material (DNA) of bladder cancer cells. |
Diagnosis, prognosis, identification of genetic markers. |
| Transcriptomic Analysis |
Study of gene expression patterns in bladder cancer cells. |
Understanding molecular mechanisms, pathways in bladder cancer development and progression. |
| Proteomic Analysis |
Study of the entire set of proteins expressed in bladder cancer cells. |
Biomarker discovery, early detection, prognostication, therapeutic response monitoring. |
| Metabolomic Analysis |
Study of small molecules (metabolites) in bladder cancer cells. |
Insights into metabolic reprogramming, potential therapeutic targets. |
Our Services
Alfa Cytology has been developing new diagnostic tools and treatments for bladder cancer through a multidisciplinary, collaborative approach that combines a number of technologies, including genomics, transcriptomics, proteomics, single-cell histology, bioinformatics and biostatistics.
Genomic
- Whole Exome Sequencing
- Targeted Gene Sequencing
- Whole Genome Sequencing
- Bladder Cancer Genotyping
Transcriptomics
- Whole Transcriptome Analysis
- Target Gene Expression Analysis
- Non-Coding RNA Analysis
- Transcriptome Profiling Array
Proteomic
- Discovery Proteomics
- Targeted Proteomics
- Post Translational Modifications (PTM) Analysis
- Exosomes Proteomics Analysis
Metabonomic
- Untargeted Metabolomics Profiling
- Targeted Metabolomics
- Lipidomics Analysis Services
- …
Multi-omics Analysis
- Transcriptome and Metabolome Integration Analysis
- Proteome and Metabolome Integration Analysis
- …
Single-Cell Omics
- Single-Cell Transcriptome Sequencing
- Single-Cell Immunome Sequencing
- Single-Cell Epigenome Sequencing
- Single-Cell Genome Sequencing
Spatial Omics
- Spatial Transcriptomics
- In Situ Sequencing
- Spatial Proteomics
- Advanced FISH Technologies
- Spatial Mass Spectrometry
Bioinformatics
- Bioinformatics Services
- Biostatistics Services
Contact Us
If you are interested in leveraging the power of omics analysis for bladder cancer research, Alfa Cytology is here to assist you. Contact us today to discuss your specific needs and learn more about how our comprehensive preclinical CRO services can accelerate your research projects, facilitate early diagnosis, and contribute to the development of effective therapies for bladder cancer.
Reference
- Yu E. Y., Zhang H., and et al. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. Curr Oncol. 2022, 29(8): 5442-5456.
For research use only. Not intended for any clinical use.
Related Services
